<DOC>
	<DOC>NCT01256736</DOC>
	<brief_summary>The purpose of this study is to evaluate 1 year extension study of the efficacy and the safety during treatment tocilizumab in patients completing treatment CWP-TCZ301 study with moderate to severe active RA and an inadequate response to current DMARD.</brief_summary>
	<brief_title>To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Patients Who have been satisfied the in/exclusion criteria of CWPTCZ301 Patients who have been withdrawn after receiving escape therapy or completed treatment during 24weeks in CWPTCZ301 study Patients who able to enroll in this study within 12 weeks after last infusion of CWPTCZ301 Willing to give written informed consent History of severe allergic or anaphylactic reactions to Investigational product in CWPTCZ301 study ALT or AST &gt; ULNⅹ2.5 Platelet count &lt; 100ⅹ103/ μL WBC &lt; 3,000/mm3 Absolute neutrophil count &lt; 1,000/mm3 Absolute lymphocyte count &lt; 500/mm3 Total bilirubin &gt; ULNⅹ2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>